Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

891 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.
Milojkovic Kerklaan B, Slater S, Flynn M, Greystoke A, Witteveen PO, Megui-Roelvink M, de Vos F, Dean E, Reyderman L, Ottesen L, Ranson M, Lolkema MP, Plummer R, Kristeleit R, Evans TR, Schellens JH. Milojkovic Kerklaan B, et al. Among authors: schellens jh. Invest New Drugs. 2016 Jun;34(3):329-37. doi: 10.1007/s10637-016-0344-9. Epub 2016 Apr 2. Invest New Drugs. 2016. PMID: 27039386 Clinical Trial.
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
Schellens JH, Heinrich B, Lehnert M, Gore ME, Kaye SB, Dombernowsky P, Paridaens R, van Oosterom AT, Verweij J, Loos WJ, Calvert H, Pavlidis N, Cortes-Funes H, Wanders J, Roelvink M, Sessa C, Selinger K, Wissel PS, Gamucci T, Hanauske AR. Schellens JH, et al. Invest New Drugs. 2002 Feb;20(1):83-93. doi: 10.1023/a:1014454821885. Invest New Drugs. 2002. PMID: 12003197 Clinical Trial.
Pharmacokinetic-pharmacodynamic guided trial design in oncology.
van Kesteren Ch, Mathôt RA, Beijnen JH, Schellens JH. van Kesteren Ch, et al. Among authors: schellens jh. Invest New Drugs. 2003 May;21(2):225-41. doi: 10.1023/a:1023577514605. Invest New Drugs. 2003. PMID: 12889741 Review.
Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours.
Schoemaker NE, Kuppens IE, Huinink WW, Lefebvre P, Beijnen JH, Assadourian S, Sanderink GJ, Schellens JH. Schoemaker NE, et al. Among authors: schellens jh. Cancer Chemother Pharmacol. 2005 Mar;55(3):263-70. doi: 10.1007/s00280-004-0874-2. Epub 2004 Nov 16. Cancer Chemother Pharmacol. 2005. PMID: 15592838 Clinical Trial.
891 results